[4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol | 161607-38-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol
• 英文别名: [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(3-pyridyl)carbinol；[4-(Tert-butyldimethylsilyloxymethyl)-phenyl]-pyridin-3-yl-methanol；[4-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]-pyridin-3-ylmethanol
• CAS: 161607-38-1
• 化学式: C₁₉H₂₇NO₂Si
• 分子量: 329.514
• InChiKey: BUEAVGAISDQTJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.69
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol 在 manganese dioxide 乙酸乙酯 、 crude mixture 、 silica gel 、 正己烷 、 ethyl acetate n-hexane 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以to provide the desired intermediate (233 mg, 65%)的产率得到4-[(tert-Butyldimethylsiloxy)methyl]phenyl pyridin-3-yl ketone
  参考文献：
  名称：

  6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist

  摘要：

  本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14；其他取代基如规范中所定义。

  公开号：

  US20120028961A1
• 作为产物：
  描述：

  对苯二甲醇 在 咪唑 、 manganese(IV) oxide 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 生成 [4-[(tert-Butyldimethylsiloxy)methyl]phenyl]-(pyridin-3-yl)carbinol
  参考文献：
  名称：

  Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives

  摘要：

  Synthesis and initial in vitro evaluation of a novel series of phenyl oxazole derivatives are described. An SAR study of the novel dual-acting TRA/TSI agent has revealed that the lipophilicity of the oxazole amide substituents greatly influences the TRA activity but not the TSI. The chain length of the alkenoic acid side chain affects both TRA and TSI. The optimal chain length for the combined activities was found to be n = 4 (heptenoic acid). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00353-9

文献信息

• 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
  申请人：ALLEN JOHN GORDON

  公开号：US20120028961A1

  公开（公告）日：2012-02-02

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is —S—R 14 ; and other substituents are as defined in the specification.

  本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14；其他取代基如规范中所定义。
• 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
  申请人：Eli Lilly and Company

  公开号：US08022062B2

  公开（公告）日：2011-09-20

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —C≡C—R10, —O—R12, —S—R14, or —NR24R25; and other substituents are as defined in the specification.

  本发明提供了式I的6-取代2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6是—C≡C—R10，—O—R12，—S—R14或—NR24R25; 其他取代基如规范中定义。
• 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist
  申请人：Allen John Gordon

  公开号：US08580780B2

  公开（公告）日：2013-11-12

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.

  本发明提供了6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物I的选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14;其他取代基如规范中所定义。
• Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives
  作者：Kumiko Takeuchi、Todd J Kohn、Dale E Mais、Timothy A True、Virginia L Wyss、Joseph A Jakubowski

  DOI：10.1016/s0960-894x(98)00353-9

  日期：1998.8

  Synthesis and initial in vitro evaluation of a novel series of phenyl oxazole derivatives are described. An SAR study of the novel dual-acting TRA/TSI agent has revealed that the lipophilicity of the oxazole amide substituents greatly influences the TRA activity but not the TSI. The chain length of the alkenoic acid side chain affects both TRA and TSI. The optimal chain length for the combined activities was found to be n = 4 (heptenoic acid). (C) 1998 Elsevier Science Ltd. All rights reserved.